vs

Side-by-side financial comparison of AtriCure, Inc. (ATRC) and Zhihu Inc. (ZH). Click either name above to swap in a different company.

AtriCure, Inc. is the larger business by last-quarter revenue ($140.5M vs $92.0M, roughly 1.5× Zhihu Inc.). Over the past eight quarters, AtriCure, Inc.'s revenue compounded faster (13.6% CAGR vs -19.0%).

AtriCure, Inc. is a global medical device company specializing in the research, development, and manufacturing of innovative surgical tools and therapeutic solutions for treating atrial fibrillation and associated cardiac conditions. Its core customers include hospitals, cardiac surgery centers, and healthcare providers across North America, Europe, and the Asia Pacific region, with products designed to support safer, more effective minimally invasive cardiac procedures.

Zhihu is a Chinese social question and answer site and news aggregator. Originally based in Chengdu and with creators from Sichuan, China, the website launched on January 26, 2011. The number of registered users on Zhihu exceeded 10 million by the end of 2013, and reached 17 million as of May 2015, with 250 million monthly page views.

ATRC vs ZH — Head-to-Head

Bigger by revenue
ATRC
ATRC
1.5× larger
ATRC
$140.5M
$92.0M
ZH
Faster 2-yr revenue CAGR
ATRC
ATRC
Annualised
ATRC
13.6%
-19.0%
ZH

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
ATRC
ATRC
ZH
ZH
Revenue
$140.5M
$92.0M
Net Profit
$30.1M
Gross Margin
75.0%
53.6%
Operating Margin
1.8%
Net Margin
32.7%
Revenue YoY
13.1%
Net Profit YoY
EPS (diluted)
$0.04

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ATRC
ATRC
ZH
ZH
Q1 26
$92.0M
Q4 25
$140.5M
Q3 25
$134.3M
$92.6M
Q2 25
$136.1M
$100.1M
Q1 25
$123.6M
$100.6M
Q4 24
$124.3M
Q3 24
$115.9M
$120.4M
Q2 24
$116.3M
$128.5M
Net Profit
ATRC
ATRC
ZH
ZH
Q1 26
$30.1M
Q4 25
Q3 25
$-267.0K
Q2 25
$-6.2M
Q1 25
$-6.7M
Q4 24
Q3 24
$-7.9M
$-1.3M
Q2 24
$-8.0M
$-11.1M
Gross Margin
ATRC
ATRC
ZH
ZH
Q1 26
53.6%
Q4 25
75.0%
Q3 25
75.5%
61.3%
Q2 25
74.5%
62.5%
Q1 25
74.9%
61.8%
Q4 24
74.5%
Q3 24
74.9%
63.9%
Q2 24
74.7%
59.6%
Operating Margin
ATRC
ATRC
ZH
ZH
Q1 26
Q4 25
1.8%
Q3 25
0.2%
-15.1%
Q2 25
-4.5%
-12.7%
Q1 25
-4.8%
Q4 24
-11.7%
Q3 24
-6.4%
-10.0%
Q2 24
-6.2%
-19.7%
Net Margin
ATRC
ATRC
ZH
ZH
Q1 26
32.7%
Q4 25
Q3 25
-0.2%
Q2 25
-4.5%
Q1 25
-5.5%
Q4 24
Q3 24
-6.8%
-1.1%
Q2 24
-6.9%
-8.6%
EPS (diluted)
ATRC
ATRC
ZH
ZH
Q1 26
Q4 25
$0.04
Q3 25
$-0.01
Q2 25
$-0.13
Q1 25
$-0.14
Q4 24
$-0.33
Q3 24
$-0.17
Q2 24
$-0.17

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ATRC
ATRC
ZH
ZH
Cash + ST InvestmentsLiquidity on hand
$167.4M
$481.8M
Total DebtLower is stronger
Stockholders' EquityBook value
$491.9M
$554.1M
Total Assets
$654.2M
$742.3M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ATRC
ATRC
ZH
ZH
Q1 26
$481.8M
Q4 25
$167.4M
Q3 25
$147.9M
$383.5M
Q2 25
$117.8M
$446.5M
Q1 25
$99.9M
$446.5M
Q4 24
$122.7M
Q3 24
$130.3M
$458.0M
Q2 24
$114.0M
$434.7M
Total Debt
ATRC
ATRC
ZH
ZH
Q1 26
Q4 25
Q3 25
$61.9M
Q2 25
$61.9M
Q1 25
$61.9M
Q4 24
Q3 24
$61.9M
Q2 24
$61.9M
Stockholders' Equity
ATRC
ATRC
ZH
ZH
Q1 26
$554.1M
Q4 25
$491.9M
Q3 25
$476.5M
$578.9M
Q2 25
$464.5M
$587.4M
Q1 25
$454.6M
$573.2M
Q4 24
$461.0M
Q3 24
$465.0M
$619.2M
Q2 24
$462.1M
$605.5M
Total Assets
ATRC
ATRC
ZH
ZH
Q1 26
$742.3M
Q4 25
$654.2M
Q3 25
$635.4M
$772.8M
Q2 25
$608.8M
$802.2M
Q1 25
$591.6M
$783.1M
Q4 24
$609.3M
Q3 24
$615.1M
$856.2M
Q2 24
$597.3M
$840.5M
Debt / Equity
ATRC
ATRC
ZH
ZH
Q1 26
Q4 25
Q3 25
0.13×
Q2 25
0.13×
Q1 25
0.14×
Q4 24
Q3 24
0.13×
Q2 24
0.13×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ATRC
ATRC
ZH
ZH
Operating Cash FlowLast quarter
$20.0M
Free Cash FlowOCF − Capex
$18.4M
FCF MarginFCF / Revenue
13.1%
Capex IntensityCapex / Revenue
1.1%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$48.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ATRC
ATRC
ZH
ZH
Q1 26
Q4 25
$20.0M
Q3 25
$26.7M
Q2 25
$21.6M
Q1 25
$-11.0M
Q4 24
$5.8M
Q3 24
$20.0M
Q2 24
$7.4M
Free Cash Flow
ATRC
ATRC
ZH
ZH
Q1 26
Q4 25
$18.4M
Q3 25
$24.1M
Q2 25
$19.0M
Q1 25
$-13.2M
Q4 24
$3.1M
Q3 24
$16.4M
Q2 24
$5.0M
FCF Margin
ATRC
ATRC
ZH
ZH
Q1 26
Q4 25
13.1%
Q3 25
18.0%
Q2 25
13.9%
Q1 25
-10.7%
Q4 24
2.5%
Q3 24
14.1%
Q2 24
4.3%
Capex Intensity
ATRC
ATRC
ZH
ZH
Q1 26
Q4 25
1.1%
Q3 25
1.9%
Q2 25
2.0%
Q1 25
1.8%
Q4 24
2.2%
Q3 24
3.1%
Q2 24
2.1%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ATRC
ATRC

Appendage Management$45.5M32%
Openheart$38.5M27%
Other$26.2M19%
Pain Management$22.6M16%
Minimally Invasive$7.7M6%

ZH
ZH

Segment breakdown not available.

Related Comparisons